search
Back to results

STEM-Parkinson's Disease

Primary Purpose

Parkinson Disease, Parkinson's Disease and Parkinsonism

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Non-invasive brainstem stimulation
Sponsored by
Scion NeuroStim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring Randomized Controlled Trial (RCT), Medical Devices, Non-Motor Symptoms (NMS), Non-Invasive Brain Stimulation

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult participants (aged 18 - 85 years inclusive)
  • Diagnosed with Parkinson's disease according to the UK Brain Bank Criteria
  • Demonstrates a positive response to oral anti-Parkinsonian medications (i.e. dopamine replacement therapies) and treated with these medications for minimum of three years prior to the screening visit
  • Report limitation to activities of daily living (e.g., writing, walking, bathing, dressing, eating, toileting, etc.)
  • Able and willing to consent to participate in the study.
  • Willing and able to comply with study requirements.
  • Anticipate being able to remain on a stable regimen of medications used for the management of PD motor and non-motor symptoms and not to introduce new medications used to treat symptoms associated with PD during the trial.
  • Fully vaccinated from COVID-19 (at least 2 weeks from their final dose) with one of the current World Health Organization evaluated vaccines, prior to Screen.
  • Have at minimum a moderate burden of non-motor symptoms associated with Parkinson's disease
  • Have a study partner (defined as someone who sees the participant for more than one hour a day, 3 times per week) that is willing to consent and participate in the trial.
  • Have capabilities to use and access smartphones and or tablets for the collection of some study data.
  • Must be willing to answer questions related to sexual interest, arousal, and performance in an interview with study staff.

Exclusion Criteria:

  • Participant anticipates being unable to attend all visits and complete all study activities.
  • Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the study trial. Women of child-bearing potential (i.e., are not yet 3 years removed from their first menopausal symptom), who are not abstinent or exclusively in same sex relationships must:

    1. Test negative for pregnancy as indicated by a negative urine pregnancy test
    2. Agree to use an approved contraception method for the entirety of the trial
  • Have a history or prior diagnosis of dementia or evidence of dementia at study screen.
  • Have experienced a myocardial infarction, angina, or stroke within the past 12 months.
  • Are receiving deep brain stimulation therapy.
  • Are treated with a pump for continuous delivery of dopamine replacement medication.
  • Use apomorphine rescue.
  • Have received MRI guided high intensity focused ultrasound within the past 12 months.
  • Experience frequent falls.
  • Work night shifts
  • Use a hearing aid that is implanted or that cannot be easily removed and replaced.
  • Have a cochlear implant.
  • Have chronic (>3 months) tinnitus.
  • Have previously been diagnosed with traumatic brain injury with ongoing sequalae.
  • Have been diagnosed with a co-morbid neurological disorder that may present with symptoms overlapping with PD (e.g., stroke, brain tumor, epilepsy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, atypical Parkinsonism or aneurysm)
  • Have unresolved complications from a previous surgical procedure at the baseline visits, such as swelling or persistent pain, that requires medical intervention.
  • Have active ear infections, or other significant ear problems.
  • Have a recent history of frequent ear infections (≥ 1 per year over the past two years)
  • Are currently enrolled or have participated in another interventional clinical trial within the last 30 days.
  • Have had eye surgery within the previous three months or ear surgery within the previous six months.
  • Have planned surgery scheduled to occur during the study that requires sedation and/or would typically be followed with a prescription for pain management.

Sites / Locations

  • Movement Disorder Center of ArizonaRecruiting
  • Cedars-Sinai Medical CenterRecruiting
  • CenExel Rocky Mountain Clinical ResearchRecruiting
  • Parkinson's Disease and Movement Disorders Center of Boca RatonRecruiting
  • Headlands Research OrlandoRecruiting
  • USF Parkinson's Disease and Movement Disorders CenterRecruiting
  • University of Kansas Medical Center - Parkinson's Disease CenterRecruiting
  • Quest ResearchRecruiting
  • Mercy Health Saint Mary'sRecruiting
  • University of New MexicoRecruiting
  • Mount Sinai HospitalRecruiting
  • Meridian Clinical ResearchRecruiting
  • Cleveland ClinicRecruiting
  • Thomas Jefferson UniversityRecruiting
  • University of PennsylvaniaRecruiting
  • Medical University of South CarolinaRecruiting
  • Veracity NeuroscienceRecruiting
  • Texas Movement Disorder SpecialistRecruiting
  • Houston Methodist Neurological InstituteRecruiting
  • Riverside Neurology SpecialistsRecruiting
  • Inland Northwest ResearchRecruiting
  • King's College Hospital NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Investigational Treatment 1

Investigational Treatment 2

Arm Description

Investigational treatment mode (stimulation pattern) 1

Investigational treatment mode (stimulation pattern) 2

Outcomes

Primary Outcome Measures

Change from baseline in The International Parkinson and Movement Disorder Society - Non-Motor Rating Scale (MDS-NMS) Total Score
The MDS-NMS is a 52-item rater-administered scale used to assess a wide range of non-motor symptoms in Parkinson's disease. Scores range between 0-832, with the higher score indicating greater non-motor symptom burden. (day 113 score - average of baseline scores from days 1 and 29)

Secondary Outcome Measures

Change from baseline in The International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total score (Sum of Parts I, II and III)
The MDS- UPDRS is a multimodal scale consisting of four parts. Part I assesses non-motor aspects of experiences of daily living and consists of two components (range 0-52). Part II is a 13- item patient-reported assessment of motor aspects of experiences of daily living. Scores range between 0-52. Part III assesses motor signs of Parkinson's disease and is completed by the rater (range of 0-132). Part III consists of 33 scores based on 18 items. In all parts, higher scores indicate more symptoms. The range for the MDS-UPDRS total (sum of parts I, II and III) is 0-236. (baseline - week 12)
Change from baseline in The International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II
The MDS-UPDRS Part II is a 13-item patient-reported assessment of motor aspects of experiences of daily living. Scores range between 0-52, with the higher score indicating greater impairment to activities of daily living. (day 113 score - average of baseline scores from days 1 and 29)
Change from baseline in the Clinical Global Impression-Improvement (CGI-I)
The CGI-I is a clinician assessment the extent of clinically meaningful change that has occurred in the patient's illness at day 113 relative to a baseline state (assessed at day 29). Changes in all aspects of Parkinson's disease (e.g., motor symptoms, non-motor symptoms and complications of anti-Parkinsonian medications) are considered.
Change from baseline in the MDS-UPDRS Part III
The MDS-UPDRS Part III is a 33-item assessment of motor function evaluated by a trained blinded rater. Scores range between 0-132 with higher scores indicating more sever motor symptoms. (day 113 score - average of baseline scores from days 1 and 29)
Change from baseline in the Parkinson's Disease Quality of Life Questionnaire Summary Index (PDQ-39 SI)
The PDQ-39 SI is a 39-item patient-reported quality of life measure that assesses how often people living with PD are affected across 8 dimensions of daily living. Scores range from 0-100, with the higher scores indicating worse perception of quality of life. (day 113 score - average of baseline scores from days 1 and 29)

Full Information

First Posted
March 10, 2021
Last Updated
July 3, 2023
Sponsor
Scion NeuroStim
search

1. Study Identification

Unique Protocol Identification Number
NCT04797611
Brief Title
STEM-Parkinson's Disease
Official Title
Non-Invasive Brainstem Modulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial (RCT)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 19, 2022 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Scion NeuroStim

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Detailed Description
Up to 218 participants will enter the double-blinded, controlled, randomized clinical trial (RCT) and will self-administer treatments twice daily in the home setting over a period of 12 weeks following a 4 week baseline period. The RCT will have 6 study visits: 3 visits at the study center and 3 visits completed in the participant's home by video call.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Parkinson's Disease and Parkinsonism
Keywords
Randomized Controlled Trial (RCT), Medical Devices, Non-Motor Symptoms (NMS), Non-Invasive Brain Stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
218 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Investigational Treatment 1
Arm Type
Other
Arm Description
Investigational treatment mode (stimulation pattern) 1
Arm Title
Investigational Treatment 2
Arm Type
Other
Arm Description
Investigational treatment mode (stimulation pattern) 2
Intervention Type
Device
Intervention Name(s)
Non-invasive brainstem stimulation
Intervention Description
Study participants will self-administer ~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
Primary Outcome Measure Information:
Title
Change from baseline in The International Parkinson and Movement Disorder Society - Non-Motor Rating Scale (MDS-NMS) Total Score
Description
The MDS-NMS is a 52-item rater-administered scale used to assess a wide range of non-motor symptoms in Parkinson's disease. Scores range between 0-832, with the higher score indicating greater non-motor symptom burden. (day 113 score - average of baseline scores from days 1 and 29)
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Change from baseline in The International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total score (Sum of Parts I, II and III)
Description
The MDS- UPDRS is a multimodal scale consisting of four parts. Part I assesses non-motor aspects of experiences of daily living and consists of two components (range 0-52). Part II is a 13- item patient-reported assessment of motor aspects of experiences of daily living. Scores range between 0-52. Part III assesses motor signs of Parkinson's disease and is completed by the rater (range of 0-132). Part III consists of 33 scores based on 18 items. In all parts, higher scores indicate more symptoms. The range for the MDS-UPDRS total (sum of parts I, II and III) is 0-236. (baseline - week 12)
Time Frame
3 months
Title
Change from baseline in The International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II
Description
The MDS-UPDRS Part II is a 13-item patient-reported assessment of motor aspects of experiences of daily living. Scores range between 0-52, with the higher score indicating greater impairment to activities of daily living. (day 113 score - average of baseline scores from days 1 and 29)
Time Frame
3 months
Title
Change from baseline in the Clinical Global Impression-Improvement (CGI-I)
Description
The CGI-I is a clinician assessment the extent of clinically meaningful change that has occurred in the patient's illness at day 113 relative to a baseline state (assessed at day 29). Changes in all aspects of Parkinson's disease (e.g., motor symptoms, non-motor symptoms and complications of anti-Parkinsonian medications) are considered.
Time Frame
3 months
Title
Change from baseline in the MDS-UPDRS Part III
Description
The MDS-UPDRS Part III is a 33-item assessment of motor function evaluated by a trained blinded rater. Scores range between 0-132 with higher scores indicating more sever motor symptoms. (day 113 score - average of baseline scores from days 1 and 29)
Time Frame
3 months
Title
Change from baseline in the Parkinson's Disease Quality of Life Questionnaire Summary Index (PDQ-39 SI)
Description
The PDQ-39 SI is a 39-item patient-reported quality of life measure that assesses how often people living with PD are affected across 8 dimensions of daily living. Scores range from 0-100, with the higher scores indicating worse perception of quality of life. (day 113 score - average of baseline scores from days 1 and 29)
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
Change from baseline in the Mini-Balance Evaluation Systems Test
Description
a measure of dynamic balance, functional mobility, and gait. This measure will be evaluated as a safety outcome to assess whether device therapy negatively impacts balance or gait for participants with Parkinson's disease (day 113 score - baseline day 29 score).
Time Frame
3 months
Title
Change from baseline in the Montreal Cognitive Assessment
Description
a screening instrument used to facilitate the assessment of cognitive impairment.
Time Frame
3 months
Title
Change from baseline in the Oral Symbol Digit Modality Test
Description
a brief and commonly used test to evaluate processing speed.
Time Frame
3 months
Title
Change from baseline in the Parkinson's Disease Sleep Scale 2
Description
an assessment to quantify nocturnal sleep issues in Parkinson's disease.
Time Frame
3 months
Title
Change from baseline in Epworth Sleepiness Scale
Description
a brief measure that is commonly used to assess daytime sleepiness.
Time Frame
3 months
Title
Change from baseline in the Parkinson Anxiety Scale
Description
a brief questionnaire to detect anxiety severity in Parkinson's disease.
Time Frame
3 months
Title
Change from baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue Scale
Description
a measure of an individual's level of fatigue during their usual daily activities over the past week.
Time Frame
3 months
Title
Change from baseline in the Geriatric Depression Scale-15
Description
a short questionnaire for assessing depression in older adults.
Time Frame
3 months
Title
Change from baseline in the MDS-NMS Non-Motor Fluctuations
Description
a rater completed assessment evaluating fluctuations of non-motor symptoms in Parkinson's disease.
Time Frame
3 months
Title
Change from baseline in the Unified Parkinson's Disease Rating Scale Part IV
Description
an assessment of complications of anti-Parkinsonian therapies.
Time Frame
3 months
Title
Change from baseline in a Non-Motor Symptom focused Clinical Global Impression-Improvement
Description
clinician assessment the extent of clinically meaningful change that has occurred as it relates to the patient's non-motor symptoms.
Time Frame
3 months
Title
Change from baseline in the Zarit Burden Interview
Description
measure of caregiving burden completed by caregivers.
Time Frame
3 months
Title
Change from baseline in the Patient Reported Outcome - Parkinson's Disease
Description
a self-rating tool to assess symptom severity in Parkinson's disease.
Time Frame
3 months
Title
Change from baseline in The Modified Schwab and England Activities of Daily Living Scale
Description
a clinical outcome assessment of an individual's ability to function independently in activities of daily living.
Time Frame
3 months
Title
Change from baseline in EncephaLogTM 3 meter Timed Up and Go Test
Description
smart phone application assessment that provides indication of risk of falls in adults.
Time Frame
3 months
Title
Change from baseline in EncephaLogTM finger tapping test
Description
smart phone application providing a quantitative measure of bradykinesia.
Time Frame
3 months
Title
Change from baseline in EncephaLogTM 10 meter Timed Up and Go Test
Description
smart phone application that measures gait and that provides indication of risk of falls in adults.
Time Frame
3 months
Title
Change from baseline in Unified Parkinson's disease Rating Scale Part I (UPDRS I)
Description
a measure of mentation, behavior, and mood in Parkinson's disease.
Time Frame
3 months
Title
Change from baseline in Hoehn & Yahr (H&Y)
Description
staging tool describing the level of disability in Parkinson's disease.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult participants (aged 18 - 85 years inclusive) Diagnosed with Parkinson's disease according to the UK Brain Bank Criteria Demonstrates a positive response to oral anti-Parkinsonian medications (i.e. dopamine replacement therapies) and treated with these medications for minimum of one year prior to the screening visit Report limitation to activities of daily living (e.g., writing, walking, bathing, dressing, eating, toileting, etc.) Able and willing to consent to participate in the study. Willing and able to comply with study requirements. Anticipate being able to remain on a stable regimen of medications used for the management of PD motor and non-motor symptoms and not to introduce new medications used to treat symptoms associated with PD during the trial. Have at minimum a moderate burden of non-motor symptoms associated with Parkinson's disease Have a study partner (defined as someone who sees the participant for more than one hour a day, 3 times per week) that is willing to consent and participate in the trial. Have capabilities to use and access smartphones and or tablets for the collection of some study data. Must be willing to answer questions related to sexual interest, arousal, and performance in an interview with study staff. Exclusion Criteria: Participant anticipates being unable to attend all visits and complete all study activities. Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the study trial. Women of child-bearing potential , who are not abstinent or exclusively in same sex relationships must: Test negative for pregnancy as indicated by a negative urine pregnancy test Agree to use an approved contraception method for the entirety of the trial Have a history or prior diagnosis of dementia or evidence of dementia at study screen. Have experienced a myocardial infarction, angina, or stroke within the past 12 months, or a transient ischemic attack within the past 6 months. Are receiving deep brain stimulation therapy. Are treated with a pump for continuous delivery of dopamine replacement medication. Use apomorphine rescue. Have received MRI guided high intensity focused ultrasound within the past 12 months. Experience frequent falls. Work night shifts Use a hearing aid that is implanted or that cannot be easily removed and replaced. Have a cochlear implant. Have chronic (>3 months) tinnitus. Have previously been diagnosed with traumatic brain injury with ongoing sequalae. Have been diagnosed with a co-morbid neurological disorder that may present with symptoms overlapping with PD (e.g., stroke, brain tumor, epilepsy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, atypical Parkinsonism or aneurysm) Have unresolved complications from a previous surgical procedure at the baseline visits, such as swelling or persistent pain, that requires medical intervention. Have active ear infections, or other significant ear problems. Have a recent history of frequent ear infections (≥ 1 per year over the past two years) Are currently enrolled or have participated in another interventional clinical trial within the last 30 days. Have had eye surgery within the previous three months or ear surgery within the previous six months. Have planned surgery scheduled to occur during the study that requires sedation and/or would typically be followed with a prescription for pain management.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kara Richardson
Phone
(984) 884-1020
Email
krichardson@scionneurostim.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jemica Warren
Phone
(984) 884-5230
Email
jwarren@scionneurostim.com
Facility Information:
Facility Name
Movement Disorder Center of Arizona
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Danica Evidente
Phone
480-526-5441
Email
danica@movementdisorders.us
Facility Name
Cedars-Sinai Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MaryClare Kelly
Phone
818-625-1282
Email
MaryClare.Kelly@cshs.org
Facility Name
CenExel Rocky Mountain Clinical Research
City
Englewood
State/Province
Colorado
ZIP/Postal Code
80113
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
https://cenexelresearch.com/rmcr/
Facility Name
Parkinson's Disease and Movement Disorders Center of Boca Raton
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
info@ParkinsonsCenter.org
Facility Name
Headlands Research Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32819
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher Galloway, MD
Phone
407-705-3471
Email
Christopher.Galloway@HeadlandsResearch.com
Facility Name
USF Parkinson's Disease and Movement Disorders Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erica Botting
Phone
813-974-8026
Email
ericabotting@usf.edu
Facility Name
University of Kansas Medical Center - Parkinson's Disease Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarina Fay
Phone
913-588-6924
Email
sfay2@kumc.edu
Facility Name
Quest Research
City
Farmington Hills
State/Province
Michigan
ZIP/Postal Code
48334
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Renee Najor
Email
renee@questri.com
First Name & Middle Initial & Last Name & Degree
Denise Morgott
Email
denise.morgott@questri.com
Facility Name
Mercy Health Saint Mary's
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stacy Smith
Email
stacy.smith@mercyhealth.com
Facility Name
University of New Mexico
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
University of New Mexico Neurology Research
Phone
505-272-0356
Facility Name
Mount Sinai Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nenad Stojiljkovic, MD
Phone
212-241-5329
Email
nenad.stojiljkovic@mssm.edu
Facility Name
Meridian Clinical Research
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Taylor Cestari
Email
tcestari@mcrmed.com
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Rozelman
Phone
216-636-1561
Email
rozelmJ@ccf.org
Facility Name
Thomas Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samantha Mayer
Email
neurologycoordinators@jefferson.edu
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lexi Kearns
Email
Lexi.Kearns@pennmedicine.upenn.edu
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lisa Heidelberg
Phone
843-876-0829
Email
heidelbe@musc.edu
Facility Name
Veracity Neuroscience
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38157
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maxine Humphrey
Email
maxine@veracityneuroscience.com
Facility Name
Texas Movement Disorder Specialist
City
Georgetown
State/Province
Texas
ZIP/Postal Code
78628
Country
United States
Individual Site Status
Recruiting
Facility Name
Houston Methodist Neurological Institute
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yvonne Subhan
Email
ysubhan@houstonmethodist.org
Facility Name
Riverside Neurology Specialists
City
Newport News
State/Province
Virginia
ZIP/Postal Code
23601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kerianne Allen
Email
Kerianne.Allen@rivhs.com
Facility Name
Inland Northwest Research
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annalise McInelly
Phone
509-960-2818
Facility Name
King's College Hospital NHS Foundation Trust
City
London
ZIP/Postal Code
SW9 8RR
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olabisi Awogbemila
Phone
+442032997189
Email
olabisi.awogbemila@nhs.net

12. IPD Sharing Statement

Learn more about this trial

STEM-Parkinson's Disease

We'll reach out to this number within 24 hrs